Replies to post #94376 on Biotech Values

[DewDiligence]

Yes, that’s the PFE compound I was referring to. It’s not listed in http://media.pfizer.com/files/research/pipeline/2010_0127/pipeline_2010_0127.pdf , so we may presume that it’s dead.

[DewDiligence]

PFE sells Idun subsidiary to Conatus for undisclosed price:

http://finance.yahoo.com/news/Conatus-Pharmaceuticals-prnews-4096055696.html?x=0&.v=1

PFE bought Idun five years ago (#msg-5533614) to acquire the company’s lead drug, a phase-2 caspase inhibitor for liver transplants secondary to HCV. After having touted this drug during investor presentations in 2007-2008, PFE stopped talking about it and the drug is not included in the PFE’s Jan 2010 pipeline chart (#msg-49123118).

All told, it’s reasonable to infer that PFE is taking a significant loss on the Idun round trip.